Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy — a real-life experience

The Egyptian Journal of Internal Medicine

Table 4 Clinical response according to underlying disease, baseline neutrophil counts, and cause of fever (day 7)

	Cefepime	Meropenem	Piperacillin/tazobactam	p-value^a	p-value^b	p-value^c
Diagnosis
ALL	5/8 (62.50)	15/17 (88.24)	10/13 (76.92)	0.133	0.410	0.477
AML	11/18 (61.11)	4/9 (44.44)	9/16 (56.25)	0.411	0.571	0.774
Others	5/7 (71.43)	6/7 (85.71)	3/4 (75.00)	0.515	0.658	0.898
ANC (cells/μl)
< 100	9/15 (60.00)	10/17 (58.82)	13/19 (68.42)	0.946	0.549	0.610
100–499	9/12 (75.00)	9/10 (90.00)	6/9 (66.67)	0.364	0.213	0.676
≥ 500	3/6 (50.00)	6/6 (100.00)	3/5 (60.00)	0.046	0.087	0.740
Cause of fever
CDI	3/9 (33.33)	5/7 (71.43)	8/12 (66.67)	0.131	0.829	0.130
MDI	6/12 (50.00)	5/10 (50.00)	4/9 (44.44)	0.990	0.809	0.801
PUO	13/16 (81.25)	15/16 (93.75)	11/15 (73.33)	0.285	0.122	0.598

^aCefepime vs meropenem, ^bmeropenem vs piperacillin/tazobactam, ^ccefepime vs piperacillin/tazobactam